Trial Profile

An Open-Label, Phase II Efficacy Trial of Doxorubicin in Combination With Dual Checkpoint Blockade Using Zalifrelimab (AGEN1884) or Botensilimab (AGEN1181) With Balstilimab (AGEN2034) for Advanced or Metastatic Soft Tissue Sarcomas

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Balstilimab (Primary) ; Botensilimab (Primary) ; Doxorubicin (Primary) ; Zalifrelimab (Primary)
Indications Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft tissue sarcoma
Focus Therapeutic Use

02 May 2025 Planned number of patients changed from 28 to 65.
26 Aug 2024 Number of treatment arms has been changed from 1 to 5.Sequential Assignment has been amended.
20 Dec 2023 Planned End Date changed from 1 Nov 2024 to 1 Nov 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com